Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Healthcare Disrupted: Next Generation Business Models and Strategies for Life Sciences

Learn how a shift from volume to value implies new roles for life sciences companies in the healthcare ecosystem. Find out more at http://bit.ly/1TVCZuq.

Related Books

Free with a 30 day trial from Scribd

See all

Healthcare Disrupted: Next Generation Business Models and Strategies for Life Sciences

  1. 1. Next Generation Business Models and Strategies by Jeff Elton and Anne O’Riordan HEALTHCARE DISRUPTED +
  2. 2. 2 + Copyright © 2016 Accenture All rights reserved. A new economic reality, market shifts and the digital revolution change the definition of what ‘health care’ actually is and how it will be delivered and experienced.
  3. 3. 3 + Copyright © 2016 Accenture All rights reserved. The shift from volume to value implies new roles in the healthcare ecosystem value chain. FROM… Volume Drivers … To Value Drivers $ Revenue Market Share Gross Margin Sales & Marketing Regulatory Medical Affairs Increased Patient Value Increased Provider Value Increased Payer Value Medical Evidence System Value Analytics Insights & Actions
  4. 4. 4 + Copyright © 2016 Accenture All rights reserved. Purchasing The new value-based healthcare paradigm will come from digitally enabled patient services. Today Value propositions focus on clinical attributes of products versus competitors’ and physician prescribers. Emerging Value propositions focus on delivering outcomes- based health & therapy management services enabled through connected devices, sensors, services, social engagement, and broadly ‘aware’ solutions. Physicians +Life Sciences Products Life Sciences Products Patients Physicians Government Payers Health System
  5. 5. Copyright © 2016 Accenture All rights reserved. 5 + To thrive in this new environment, there are strategic choices no healthcare company can avoid. Senior leaders will need to: Clarify their company’s market positioning regarding patient outcomes and value to the healthcare system. Define the differentiating capabilities necessary to deliver on those goals. Create a high-performance enterprise of partners, collaborators and talent.
  6. 6. 6 + Copyright © 2016 Accenture All rights reserved. Introducing four emerging business models to drive the shift from ‘volume to value’: Around-the-Patient Innovators Economics tied to improving patient and health systems achieved by integrating therapeutics, devices and services with clinical management processes. Lean Innovators Combine the best practices of efficient manufacturing and lean supply chain with M&A expertise, challenging existing cost structures and operating models. New Health Digitals Economics grounded in digital with global scale and ecosystems of apps, technologies, devices and the cloud who are changing how and where patient care is delivered. Value Innovators Product-centric, focused on specialty therapeutics and the patient journey, using services leveraging analytics and to improve outcomes. Learn More
  7. 7. 7 + Copyright © 2016 Accenture All rights reserved. Is your organization built for collaboration and competition? More Info Buy Now
  8. 8. 8 + Copyright © 2016 Accenture All rights reserved. Anne O'Riordan is the Global Industry Senior Managing Director of Accenture Life Sciences. Based in China since 2007, she has worked throughout Europe, the United States, and Asia for the past 25 years, helping pharmaceutical, medical technology, and consumer health companies rethink, reshape, and restructure their businesses to deliver better patient outcomes. Before moving to Asia, O’Riordan was based in London for nine years, where she led Accenture’s European Health and Life Sciences practice. About the Authors Jeff Elton, Ph.D., is a Managing Director in Accenture Strategy, and Global Lead of Accenture Predictive Health Intelligence and Accenture Intelligent Patient Solutions, which is focused on advancing real-world analytics and the next generation of business models for healthcare organizations and companies. Currently a board member of the Massachusetts Biotechnology Council, Elton has more than 25 years of experience as a global executive and consultant in the healthcare and life sciences field.

×